No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - General
Abbott India Limited is an Indian pharmaceutical enterprise primarily engaged in the development and distribution of a diverse range of medicinal products. Its extensive portfolio addresses critical therapeutic areas such as women's health, gastroenterology, metabolic disorders, central nervous system conditions, and vaccines. The company also offers multi-specialty solutions for insomnia, vitamin D deficiency, pre-term labor, and pain management, alongside anti-infectives, cardio-diabetic treatments, hormones, respiratory care, hepatic products, and consumer health items. Founded in 1910, the company's main office is located in Mumbai, India, and it operates as a subsidiary of Abbott Capital India Limited.
www.abbott.co.inNo one on the platform currently holds ABBOTINDIA.BO.
No tracked institution reports a position in ABBOTINDIA.BO as of their last filing.
No one on the platform has traded ABBOTINDIA.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 50.9% | 33.5% | 27.5% | — | — | — |
| Rev. Growth % | 8.1% | 10.0% | ||||
| Profit Margin % | 22.4% | 19.8% | 16.4% | |||
| Free Cash Flow Margin % | 24.0% | 18.7% | 15.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $75.1B | +8.5% | $814.15 | $717.10–$897.47 | — | 8 |
| 2028 | $82.2B | +9.4% | $905.61 | $837.09–$986.06 | — | 4 |
| 2029 | $90.0B | +9.5% | $1008.29 | $931.99–$1097.85 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | $203.45 | $201.70 | -0.9% |
| 2026-05-11 | $186.70 | $185.80 | -0.5% |
| 2026-02-12 | $185.00 | $187.05 | +1.1% |
| 2025-11-06 | $181.55 | $195.40 | +7.6% |
| 2025-08-12 | $191.00 | $172.30 | -9.8% |
| 2025-05-15 | $158.00 | $173.00 | +9.5% |
| 2025-02-05 | $163.00 | $169.90 | +4.2% |
| 2024-11-07 | $166.00 | $168.80 | +1.7% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| ABBOTINDIA.BOAbbott India Limited | $26143.35 | +2.24% | $556.1B | — |
| ALKEM.BOAlkem Laboratories Limited | $5155.00 | +1.29% | $615.4B | — |
| ALKEM.NSAlkem Laboratories Limited | $5161.00 | +1.44% | $617.1B | — |
| AUROPHARMA.BOAurobindo Pharma Limited | $1664.90 | -0.63% | $957.6B | — |
| AUROPHARMA.NSAurobindo Pharma Limited |
| $1660.00 |
| -1.18% |
| $955.1B |
| — |
| GLAND.BOGland Pharma Limited | $2880.45 | -1.69% | $474.9B | — |
| GLAXO.BOGlaxoSmithKline Pharmaceuticals Limited | $2814.10 | -0.56% | $474.6B | — |
Source: Financial Modeling Prep · peers by sector/industry